CHARACTERISTICS OF EXPRESSION OF SOME IMMUNOHISTOCHEMICAL MARKERS IN PATIENTS WITH STAGE IIIC-IV OVARIAN CANCER AS A CRITERION OF EFFECTIVENESS OF CHEMOIMMUNOTHERAPY

Aim. To analyze the expression of the p53 and Ki67 markers in patients with stage IIIC-IV ovarian cancer by immunohistochemical (IHC) method as a criterion for the treatment effectiveness. Materials and Methods. The study included 93 patients with ovarian cancer stage IIIC-IV aged 34-77 years. The patients were divided into 4 groups: group 1 – with neoadjuvant chemotherapy and intramuscular injections of recombinant interferon-gamma; group 2 – with neoadjuvant chemotherapy and intraperitoneal injections of recombinant interferon-gamma; group 3 (controls) – standard chemotherapy without interferon-gamma; group 4 (comparison group) – with surgery as the first stage of treatment. All tumor samples were studied by IHC method for the expression of p53 protein and Кi-67 marker of proliferative activity. Results. Neoadjuvant chemotherapy did not affect the levels of p53, compared to the group without chemotherapy. Inclusion of interferon-gamma to neoadjuvant chemotherapy resulted in statistically significant decrease in p53 expression, mainly with intraperitoneal administration. Study of proliferative potential of tumors in patients with intraperitoneal injections of interferon-gamma showed 1.3 times higher predomination of tumors with low proliferative activity compared to patients with intramuscular administration, 3.5 times higher compared to the group receiving chemotherapy without interferon-gamma, and 7 times higher than in patients with surgery. High proliferative activity was noted only in tumor cells of patients without neoadjuvant chemotherapy. Conclusions. The IHC study demonstrated that inclusion of interferon-gamma to chemotherapy decreases proliferative potential of tumors and expression of р53 by tumor cells in ovarian cancer patients, especially with intraperitoneal introduction in the course of neoadjuvant chemotherapy.